Pradžia › Vilkligės nefritas › Ohio
Vilkligės nefritas klinikiniai tyrimai Ohio
7 tyrimai dėl Vilkligės nefritas ieško dalyvių vietose Ohio.
Miestai Ohio
Oficialus tyrimo tekstas (anglų kalba)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Cleveland Clinic Foundation, Cleveland
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT05268289The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- Akron Children's Hospital, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University Hospitals Cleveland Medical Center, Cleveland
- ir dar 1
Renkami dalyviai2 fazė
Amžius nuo 8 iki 20 · Visoms lytims · Atnaujinta 2026-09-14 · NCT05538208A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Cincinnati Childrens Hospital, Cincinnati
Renkami dalyviai2 fazė
Amžius nuo 5 iki 17 · Visoms lytims · Atnaujinta 2026-09-03 · NCT05039619Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
- GSK Investigational Site, Columbus
Renkami dalyviaiStebimasis tyrimas
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-02 · NCT06527872A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- MetroHealth, Cleveland
Renkami dalyviai1 fazė
Amžius nuo 12 iki 70 · Visoms lytims · Atnaujinta 2026-05-22 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- The MetroHealth System, Cleveland
Renkami dalyviaiStebimasis tyrimas
Amžius nuo 18 iki 110 · Visoms lytims · Atnaujinta 2026-04-15 · NCT05934149Safety and Efficacy of Combination Belimumab and Voclosporin in the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Trial
- Nephrology Clinical Trials Unit The Ohio State University Wexner Medical Center, Columbus
Renkami dalyviai4 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2025-11-06 · NCT07225387Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.